Anthrax antigenic compositions
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 26, 2005
app pub date -
Dec 15, 2004
filing date -
Nov 1, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
An antigenic pharmaceutical composition is provided comprising Protective Antigen (PA) and Lethal Factor (LF), wherein said PA and/or LF lacks a functional binding site, thereby preventing said PA and LF from binding together via said binding site or thereby preventing said PA from binding to a native PA cell receptor via said binding site, and wherein said composition is substantially non-toxic to animal cells. The composition is for preventing or minimising anthrax toxicity in mammals, preferably in humans. Also provided are DNA and RNA based vaccines encoding the antigenic components of said pharmaceutical composition. The present specification also describes antibodies that bind to at least one of PA, LF or EF, which binding thereby prevents:--(i) PA from binding to LF or EF, or to a native PA cell receptor; or (ii) LF from binding to PA; or (iii) EF from binding to PA.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully